- Home
- RCAT vs CELC Comparison
RCAT vs CELC Comparison
Compare RCAT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCAT
- CELC
- Stock Information
- Founded
- RCAT 2002
- CELC 2011
- Country
- RCAT United States
- CELC United States
- Employees
- RCAT N/A
- CELC N/A
- Industry
- RCAT Wholesale Distributors
- CELC Medical Specialities
- Sector
- RCAT Industrials
- CELC Health Care
- Exchange
- RCAT Nasdaq
- CELC Nasdaq
- Market Cap
- RCAT N/A
- CELC 391.0M
- IPO Year
- RCAT 2017
- CELC 2017
- Fundamental
- Price
- RCAT $5.89
- CELC $10.24
- Analyst Decision
- RCAT Strong Buy
- CELC Strong Buy
- Analyst Count
- RCAT 2
- CELC 6
- Target Price
- RCAT $8.50
- CELC $30.17
- AVG Volume (30 Days)
- RCAT 4.0M
- CELC 274.7K
- Earning Date
- RCAT 03-31-2025
- CELC 05-14-2025
- Dividend Yield
- RCAT N/A
- CELC N/A
- EPS Growth
- RCAT N/A
- CELC N/A
- EPS
- RCAT N/A
- CELC N/A
- Revenue
- RCAT $16,468,647.00
- CELC N/A
- Revenue This Year
- RCAT $113.68
- CELC $49.98
- Revenue Next Year
- RCAT $206.40
- CELC N/A
- P/E Ratio
- RCAT N/A
- CELC N/A
- Revenue Growth
- RCAT 95.46
- CELC N/A
- 52 Week Low
- RCAT $0.75
- CELC $8.53
- 52 Week High
- RCAT $15.27
- CELC $22.04
- Technical
- Relative Strength Index (RSI)
- RCAT 45.85
- CELC 44.81
- Support Level
- RCAT $5.44
- CELC $9.98
- Resistance Level
- RCAT $6.20
- CELC $10.70
- Average True Range (ATR)
- RCAT 0.46
- CELC 0.66
- MACD
- RCAT 0.23
- CELC 0.08
- Stochastic Oscillator
- RCAT 76.16
- CELC 40.38
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.